The U.S. Supreme Court on Monday temporarily restored access to the abortion pill mifepristone by allowing mail-order prescriptions to continue, pausing a Fifth Circuit Court of Appeals decision that had severely limited access to the drug.
Why it matters: The one-week stay issued by Justice Samuel Alito does not resolve the underlying legal dispute over federal rules for dispensing mifepristone. However, it provides clarity for pharmacies, telehealth providers, and patients in states where abortion remains legal, reducing confusion over prescription regulations.
Key developments:
- The Supreme Court’s order responds to emergency requests from Danco Laboratories and GenBioPro, the manufacturers of mifepristone, to reinstate access via teleprescribing and mail delivery.
- Parties involved in the case must file responses by Thursday.
- The order follows a Fifth Circuit ruling on Friday, which sided with Louisiana in a lawsuit challenging Biden administration policies that expanded access to mifepristone.
Louisiana had argued that the federal rules undermined state laws protecting fetal life and forced the state to spend Medicaid funds on emergency care for women who experienced complications from the drug.
This remains a developing story. Further updates will be provided as new information becomes available.